---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000502"
form_type: "8-K"
ticker: "LNAI"
cik: "0001527728"
company_name: "Lunai Bioworks Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:22:16.979309+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lunai Bioworks enters $20M strategic acquisition; exchanges $828K debt for equity

## Summary
- Debt exchange: $828,770.14 principal and interest canceled for 3,909,293 shares at $0.21/share and warrants exercisable at $0.21 through 2036.
- Enters $20M strategic transaction for BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group.
- Transaction structured as Series B Convertible Preferred at fixed $1.50 conversion price; no variable pricing or reset provisions.
- Platform enables compounds to cross BBB, remain inactive systemically, and activate in the brain; targets acetylcholinesterase pathways.
- CEO David Weinstein says transaction is a 'step-change' for CNS delivery capabilities.

## SEC filing metadata
- accession: 0001731122-26-000502
- form_type: 8-K
- ticker: LNAI
- cik: 0001527728
- company_name: Lunai Bioworks Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/e7507_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000502
- JSON: https://secwatch.observer/filing/0001731122-26-000502.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000502.txt

## Key facts
- Material Agreements
  Lunai Bioworks Inc. entered into Debt Exchange Agreements with three of the Company’s holders of secured promissory notes valued at $828,770.14 (effective 2026-03-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: three of the Company’s holders of secured promissory notes
  - Value: $828,770.14
  - Effective: 2026-03-24
  source text: On March 24, 2026, Lunai Bioworks, Inc. (the “Company”) entered into separate debt exchange agreements (collectively, the “Debt Exchange Agreements”) with three of the Company’s holders (each a “Holder”) of secured promissory notes (the “Investor Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm
- Material Agreements
  Lunai Bioworks Inc. entered into Acquisition Agreement with Clemann Group, SAS valued at $20.0 million (effective 2026-03-26).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Clemann Group, SAS
  - Value: $20.0 million
  - Effective: 2026-03-26
  source text: On March 26, 2026, the Company entered into a binding agreement (the “Acquisition Agreement”) with Clemann Group, SAS, or its assignee (the “Seller”), pursuant to which the Company agreed to acquire certain blood-brain barrier delivery technology and central nervous system Alzheimer’s drug assets (the “Transaction”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1527728/000173112226000502/0001731122-26-000502-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.